# ALTA-2 (NCT03535740)

> A Study of Brigatinib in Participants With Anaplastic Lymphoma Kinase-Positive (ALK+), Advanced Non-Small-Cell Lung Cancer (NSCLC) Progressed on Alectinib or Ceritinib

No report yet. It can be ordered.

- Drugs tested: brigatinib
- Indication: ALK-positive advanced NSCLC progressed on alectinib or ceritinib

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03535740
- Phase: PHASE2
- Status: COMPLETED
- Sponsor: Ariad Pharmaceuticals
- Conditions: ALK-positive Advanced NSCLC
- Interventions: Brigatinib
- Enrollment: 103
- Primary outcome: Confirmed Objective Response Rate (ORR) Using RECIST v1.1 as Assessed by the Independent Review Committee (IRC)

## Indexed commentary on ALTA-2 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 6

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=alta-2-nct03535740